Clinical development of MVA-based therapeutic cancer vaccines

References

• Moss B. Vaccinia virus: a tool for research and vaccine development. Science252(5013), 1662–1667 (1991).
   PubMed Web of Science ®Google Scholar
• Dick G. Routine smallpox vaccination. Br. Med. J.3(5767), 163–166 (1971).
   Google Scholar
• Kempe CH. The end of routine smallpox vaccination in the United States. Pediatrics49(4), 489–492 (1972).
   PubMedGoogle Scholar
• Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature317(6040), 813–815 (1985).
   PubMed Web of Science ®Google Scholar
• Acres B, Dott K, Stefani L, Kieny MP. Directed cytokine expression in tumor cells in vivo using recombinant vaccinia virus. Ther. Immunol.1(1), 17–23 (1994).
   PubMedGoogle Scholar
• Foloppe J, Kintz J, Futin N et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. (2008) (Epub ahead of print) DOI: 10.1038/gt.2008.82.
   Google Scholar
• Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther.11(2), 180–195 (2005).
   PubMed Web of Science ®Google Scholar
• Kieny MP, Lathe R, Drillien R et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature312(5990), 163–166 (1984).
   PubMed Web of Science ®Google Scholar
• Brochier B, Kieny MP, Costy F et al.Large-scale eradication of rabies using recombinant vaccinia–rabies vaccine. Nature354(6354), 520–522 (1991).
   PubMed Web of Science ®Google Scholar
• Kieny MP, Gautier C, Tomasetto C et al.Vaccination against polyoma virus (PyV) tumors using vaccinia-PyV recombinants: a major tumor-specific transplantation antigen (TSTA) epitope resides within the C-terminal segment of middle-T protein. Int. J. Cancer45(1), 185–189 (1990).
   Google Scholar
• Hareuveni M, Gautier C, Kieny MP, Wreschner D, Chambon P, Lathe R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl Acad. Sci. USA87(23), 9498–9502 (1990).
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst.84(14), 1084–1091 (1992).
   PubMed Web of Science ®Google Scholar
• Cole DJ, Wilson MC, Baron PL et al. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Hum. Gene Ther.7(11), 1381–1394 (1996).
   PubMed Web of Science ®Google Scholar
• Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother.23(5), 570–580 (2000).
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM et al. A Phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer75(1), 34–42 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine6(6), 466–468 (1988).
   PubMed Web of Science ®Google Scholar
• Wild F, Giraudon P, Spehner D, Drillien R, Lecocq JP. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine8(5), 441–442 (1990).
   PubMed Web of Science ®Google Scholar
• Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol.68(12), 8125–8130 (1991).
   Google Scholar
• Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox–CEA(6D)–TRICOM alone and sequentially with vaccinia–CEA(6D)–TRICOM, with and without granulocyte–macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol.23(4), 720–731 (2005).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res.12(4), 1260–1269 (2006).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA–MUC-1–TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res.14(10), 3060–3069 (2008).
   PubMed Web of Science ®Google Scholar
• Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology188(1), 217–232 (1992).
   PubMed Web of Science ®Google Scholar
• Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA93(21), 11349–11353 (1996).
   PubMed Web of Science ®Google Scholar
• Mayr A, Hochstein-Mintzel V, Stickl H. [Derivation, characterization and use of the attenuated vaccinia strain MVA]. Infection3, 6–14 (1975).
   Google Scholar
• Stickl H, Hochstein-Mintzel V, Mayr A et al. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med. Wochenschr.99, 2386–2392 (1974).
   PubMed Web of Science ®Google Scholar
• Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. (B)167(5–6), 375–390 (1978).
   PubMedGoogle Scholar
• Gómez CE, Nájera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther.8(2), 97–120 (2008).
   PubMed Web of Science ®Google Scholar
• Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother.50(8), 397–407 (2001).
   PubMed Web of Science ®Google Scholar
• Erbs P, Findeli A, Kintz J et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther.15(1), 18–28 (2008).
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med.9(6), 729–735 (2003).
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Moorthy VS, Andrews L et al. Synergistic DNA–MVA prime–boost vaccination regimes for malaria and tuberculosis. Vaccine24(21), 4554–4561 (2006).
   PubMed Web of Science ®Google Scholar
• Fournillier A, Gerossier E, Evlashev A et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine25(42), 7339–7353 (2007).
   PubMedGoogle Scholar
• Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol.85(Pt 4), 911–919 (2004).
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med.5(8), 690–699 (2003).
   PubMed Web of Science ®Google Scholar
• Mulryan K, Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther.1(12), 1129–1137 (2002).
   PubMed Web of Science ®Google Scholar
• Meyer RG, Britten CM, Siepmann U et al. A Phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol. Immunother.54(5), 453–467 (2005).
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Mortarini R et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a Phase I trial in metastatic melanoma. Clin. Cancer Res.10(16), 5381–5390 (2004).
   PubMed Web of Science ®Google Scholar
• Smith CL, Dunbar PR, Mirza F et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer113(2), 259–266 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Dangoor A, Keilholz U et al. Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. J. Clin. Oncol.24(18 Suppl.), 8030 (2006).
   Google Scholar
• Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther.7(9), 1463–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Cao J, Hernandez-McClain J, Willis R et al. Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-α (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC). ASCO Meeting Abstracts25, 3069 (2007).
   Google Scholar
• Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res.13(15 Pt 1), 4487–4494 (2007).
   PubMed Web of Science ®Google Scholar
• Amato RJ, Drury N, Naylor S et al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a Phase II trial. J. Immunother.31(6), 577–585 (2008).
   PubMed Web of Science ®Google Scholar
• Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines4(4), 493–502 (2005).
   PubMed Web of Science ®Google Scholar
• Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother.23(5), 570–580 (2008).
   Google Scholar
• Scholl S, Squiban P, Bizouarne N et al. Metastatic breast tumor regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J. Biomed. Biotechnol.2003(3), 194–201 (2003).
   PubMedGoogle Scholar
• Pantuck AJ, van Ophoven A, Gitlitz BJ et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J. Immunother.27(3), 240–253 (2004).
   PubMed Web of Science ®Google Scholar
• Acres B. Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA–MUC1–IL2). J. BUON12(Suppl. 1), S71–S75 (2007).
   PubMedGoogle Scholar
• Dreicer R, Ahmann FR, Pantuck AJ et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer with biochemical failure. J. Clin. Oncol.2005 ASCO Annual Meeting Proceedings.23(16S), 4518 (2005).
   Google Scholar
• Banu E, Rixe O, Linassier C et al. A Phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). J. Clin. Oncol.2005 ASCO Annual Meeting Proceedings24(18S), 2581 (2008).
   Google Scholar
• Velu T, Ramlau R, Quoix E et al. A Phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with non small cell lung cancer. J. Clin. Oncol.2005 ASCO Annual Meeting Proceedings23(16S), 7132 (2005).
   Google Scholar
• Ramlau R, Quoix E, Rolski J et al. A Phase II study of TG4010 (MVA–MUC1–IL2) in association with chemotherapy in patients with stage III/IV non small cell lung cancer. J. Thor. Oncol.3(7), 735–744 (2008).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Westeel V, Papai Z et al. Randomized Phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA–MUC1–IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 8023).
   Google Scholar